MUSTARGEN (mechlorethamine hydrochloride) by Recordati is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 1949.
Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
MUSTARGEN (mechlorethamine HCl) is a classic nitrogen mustard alkylating agent approved in 1949 for cancer treatment. It works by cross-linking DNA through alkylating activity, disrupting cancer cell replication. This injectable chemotherapy is used in select hematologic and solid tumor indications where alkylating mechanisms remain relevant.
This legacy product is approaching loss of exclusivity with minimal linked job opportunities, signaling a small or consolidated commercial team focused on maintenance rather than growth.
Alkylating Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MUSTARGEN offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Roles on this product are typically maintenance-focused, suitable for early-career professionals seeking stability or experienced leaders managing legacy portfolios at Recordati.
Worked on MUSTARGEN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.